162 related articles for article (PubMed ID: 17221297)
21. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach.
Ukawa H; Yamakuni H; Kato S; Takeuchi K
Dig Dis Sci; 1998 Sep; 43(9):2003-11. PubMed ID: 9753266
[TBL] [Abstract][Full Text] [Related]
22. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.
Wallace JL; McKnight W; Reuter BK; Vergnolle N
Gastroenterology; 2000 Sep; 119(3):706-14. PubMed ID: 10982765
[TBL] [Abstract][Full Text] [Related]
23. Central ghrelin gastroprotection involves nitric oxide/prostaglandin cross-talk.
Sibilia V; Pagani F; Rindi G; Lattuada N; Rapetti D; De Luca V; Campanini N; Bulgarelli I; Locatelli V; Guidobono F; Netti C
Br J Pharmacol; 2008 Jun; 154(3):688-97. PubMed ID: 18414388
[TBL] [Abstract][Full Text] [Related]
24. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent.
Sun WH; Tsuji S; Tsujii M; Gunawan ES; Kawai N; Kimura A; Kakiuchi Y; Yasumaru M; Iijima H; Okuda Y; Sasaki Y; Hori M; Kawano S
J Pharmacol Exp Ther; 2000 Nov; 295(2):447-52. PubMed ID: 11046075
[TBL] [Abstract][Full Text] [Related]
25. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
26. Prostaglandin E prevents indomethacin-induced gastric and intestinal damage through different EP receptor subtypes.
Kunikata T; Araki H; Takeeda M; Kato S; Takeuchi K
J Physiol Paris; 2001; 95(1-6):157-63. PubMed ID: 11595431
[TBL] [Abstract][Full Text] [Related]
27. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Kato S; Ogawa Y; Kanatsu K; Okayama M; Watanabe T; Arakawa T; Takeuchi K
J Pharmacol Exp Ther; 2002 Nov; 303(2):503-9. PubMed ID: 12388629
[TBL] [Abstract][Full Text] [Related]
28. Cyclooxygenase (COX)-1 and COX-2 both play an important role in the protection of the duodenal mucosa in cats.
Satoh H; Amagase K; Ebara S; Akiba Y; Takeuchi K
J Pharmacol Exp Ther; 2013 Jan; 344(1):189-95. PubMed ID: 23008503
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses.
Takeuchi K; Suzuki K; Yamamoto H; Araki H; Mizoguchi H; Ukawa H
J Physiol Pharmacol; 1998 Dec; 49(4):501-13. PubMed ID: 10069692
[TBL] [Abstract][Full Text] [Related]
30. Interaction between NSAIDs and steroid in rat stomach: safety of nimesulide as a preferential COX-2 inhibitor in the stomach.
Kataoka H; Horie Y; Koyama R; Nakatsugi S; Furukawa M
Dig Dis Sci; 2000 Jul; 45(7):1366-75. PubMed ID: 10961716
[TBL] [Abstract][Full Text] [Related]
31. Selective cyclooxygenase (COX) inhibition causes damage to portal hypertensive gastric mucosa: roles of nitric oxide and NF-kappaB.
Akahoshi T; Tanigawa T; Sarfeh IJ; Chiou SK; Hashizume M; Maehara Y; Jones MK
FASEB J; 2005 Jul; 19(9):1163-5. PubMed ID: 15845610
[TBL] [Abstract][Full Text] [Related]
32. Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Pawlik M; Pajdo R; Kwiecien S; Ptak-Belowska A; Sliwowski Z; Mazurkiewicz-Janik M; Konturek SJ; Pawlik WW; Brzozowski T
J Physiol Pharmacol; 2011 Feb; 62(1):75-86. PubMed ID: 21451212
[TBL] [Abstract][Full Text] [Related]
33. Intestinal effects of nonselective and selective cyclooxygenase inhibitors in the rat.
Menozzi A; Pozzoli C; Giovannini E; Solenghi E; Grandi D; Bonardi S; Bertini S; Vasina V; Coruzzi G
Eur J Pharmacol; 2006 Dec; 552(1-3):143-50. PubMed ID: 17069793
[TBL] [Abstract][Full Text] [Related]
34. Oral but not parenteral aspirin upregulates COX-2 expression in rat stomachs. a relationship between COX-2 expression and PG deficiency.
Mashita Y; Taniguchi M; Yokota A; Tanaka A; Takeuchi K
Digestion; 2006; 73(2-3):124-32. PubMed ID: 16804302
[TBL] [Abstract][Full Text] [Related]
35. Non-ulcerogenic dose of dexamethasone delays gastric ulcer healing in rats.
Luo JC; Shin VY; Liu ES; So WH; Ye YN; Chang FY; Cho CH
J Pharmacol Exp Ther; 2003 Nov; 307(2):692-8. PubMed ID: 12966148
[TBL] [Abstract][Full Text] [Related]
36. Dexamethasone impairs the gastric mucosal integrity in rats treated with a cyclooxygenase-1 but not with a cyclooxygenase-2 inhibitor.
Peskar BM; Ehrlich K; Egger T; Sattler W
Pharmacology; 2006; 76(4):180-4. PubMed ID: 16491041
[TBL] [Abstract][Full Text] [Related]
37. Gastric motility and mucosal ulcerogenic responses induced by prokinetic drugs in rats under prostaglandin-deficient conditions.
Takeuchi K; Kato S; Hirata T; Nishiwaki H
Dig Dis Sci; 1997 Feb; 42(2):251-8. PubMed ID: 9052502
[TBL] [Abstract][Full Text] [Related]
38. Role of cyclooxygenase isoforms in gastric mucosal defence.
Peskar BM
J Physiol Paris; 2001; 95(1-6):3-9. PubMed ID: 11595412
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-1 suppresses lipopolysaccharide-induced changes in rat gastric inducible nitric oxide synthase.
West SD; Suliburk JW; Helmer KS; Mercer DW
Crit Care Med; 2008 Feb; 36(2):572-9. PubMed ID: 18216606
[TBL] [Abstract][Full Text] [Related]
40. COX inhibition and NSAID-induced gastric damage--roles in various pathogenic events.
Takeuchi K; Tanaka A; Hayashi Y; Yokota A
Curr Top Med Chem; 2005; 5(5):475-86. PubMed ID: 15974942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
